2 articles
Imperial College London spinout MintNeuro signed a multi-year commercial supply agreement on 6 May 2026 to provide its miniaturised sensing and stimulation integrated circuits to Motif Neurotech's DOT depression implant across pre-clinical, early clinical, and pivotal trial phases. The deal lands two weeks after Motif's FDA Investigational Device Exemption clearance.
The FDA has approved Motif Neurotech's investigational device exemption to begin a first-in-patient clinical trial of DOT, a millimeter-scale epidurally implanted wirelessly powered brain stimulator that targets the prefrontal cortex. The Rice University spinout, backed by former Neuralink president Max Hodak among others, becomes one of the first companies to attempt an implantable depression therapy at the size and patient-acceptance profile that has eluded every prior DBS-for-depression programme.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.